Search Results - "Mihályová, Jana"

Promising Immunotherapeutic Modalities for B-Cell Lymphoproliferative Disorders by Mihályová, Jana, Hradská, Katarína, Jelínek, Tomáš, Motais, Benjamin, Celichowski, Piotr, Hájek, Roman

“…Over the last few years, treatment principles have been changed towards more targeted therapy for many B-cell lymphoma subtypes and in chronic lymphocytic…”
Get full text

External validation of International Prognostic Score for asymptomatic early stage chronic lymphocytic leukaemia and proposal of an alternative score by Smolej, Lukáš, Turcsányi, Peter, Kubová, Zuzana, Zuchnická, Jana, Mihályová, Jana, Šimkovič, Martin, Vodárek, Pavel, Krčméryová, Mária, Móciková, Heidi, Brejcha, Martin, Špaček, Martin

“…Summary Most patients with chronic lymphocytic leukaemia (CLL) are nowadays diagnosed without any symptoms and do not require therapy. A prognostic score…”
Get full text

Idelalisib plus rituximab versus ibrutinib in the treatment of relapsed/refractory chronic lymphocytic leukaemia: A real‐world analysis from the Chronic Lymphocytic Leukemia Patients Registry (CLLEAR) by Špaček, Martin, Smolej, Lukáš, Šimkovič, Martin, Nekvindová, Lucie, Křístková, Zlatuše, Brychtová, Yvona, Panovská, Anna, Mašlejová, Stanislava, Bezděková, Lucie, Écsiová, Dominika, Vodárek, Pavel, Zuchnická, Jana, Mihályová, Jana, Urbanová, Renata, Turcsányi, Peter, Lysák, Daniel, Novák, Jan, Brejcha, Martin, Líkařová, Tereza, Vodička, Prokop, Baranová, Jana, Trněný, Marek, Doubek, Michael

“…Summary Idelalisib (idela), a phosphatidylinositol 3‐kinase inhibitor, and ibrutinib, a Bruton tyrosine kinase inhibitor, were the first oral targeted agents…”
Get full text

COVID-19 in patients with chronic lymphocytic leukemia: a multicenter analysis by the Czech CLL study group by Šimkovič, Martin, Turcsányi, Peter, Špaček, Martin, Mihályová, Jana, Ryznerová, Pavlína, Maco, Mária, Vodárek, Pavel, Écsiová, Dominika, Poul, Hynek, Móciková, Heidi, Zuchnická, Jana, Panovská, Anna, Lekaa, Mohammad, Oršulová, Martina, Prchlíková, Adéla, Stejskal, Lukáš, Mašlejová, Stanislava, Brychtová, Yvona, Bezděková, Lucie, Papajík, Tomáš, Lysák, Daniel, Trněný, Marek, Smolej, Lukáš, Doubek, Michael

“…Patients with chronic lymphocytic leukemia (CLL) have a high risk of poor outcomes related to coronavirus disease 2019 (COVID-19). This multicenter cohort…”
Get full text

Management of Treatment-Related Infectious Complications in High-Risk Hemato-Oncological Patients via Telemedicine by Hradská, Katarína, Popková, Tereza, Skořupová, Michaela, Mihályová, Jana, Jelínek, Tomáš, Lančová, Jana, Schellong, Norbert, Hájek, Roman

“…Infectious complications, especially febrile neutropenia, in hemato-oncological patients are associated with considerable morbidity, mortality and expenses…”
Get full text

Practical aspects of CAR-T cell therapy by Jana, Mihályová, Tomáš, Jelínek, Michal, Kaščák, Kateřina, Benková, Juraj, Uraš, Ivo, Demel, Zdeněk, Kořístek, Roman, Hájek

“…Chimeric antigen receptor (CAR) T cell therapy has been gradually building its position in the treatment of hematological malignancies. Currently, there are…”
Get more information

CD38 targeted treatment for multiple myeloma by Jelínek, Tomáš, Mihályová, Jana, Hájek, Roman

“…CD38 antigen is highly and uniformly expressed on plasma cells and thus represents an ideal target for the treatment of multiple myeloma (MM) with…”
Get more information

Osteolytic bone lesions, hypercalcemia and paraprotein, but not a myeloma: case report and review of literature by Hradská, Katarína, Jelínek, Tomáš, Ďuraš, Juraj, Mihályová, Jana, Popková, Tereza, Cvek, Jakub, Bukovanský, Kamil, Havel, Martin, Spáčilová, Veronika, Hájek, Roman

“…In June 2018, 77-year-old man was referred to The Department of Haematooncology, University Hospital Ostrava, for suspicion of multiple myeloma. This was…”
Get more information

PD‐1/PD‐L1 inhibitors in haematological malignancies: update 2017 by Jelinek, Tomas, Mihalyova, Jana, Kascak, Michal, Duras, Juraj, Hajek, Roman

“…Summary The introduction of PD‐1/PD‐L1 pathway inhibitors is an important landmark in solid oncology with unprecedented practice‐changing activity in various…”
Get full text

Venetoclax: A new wave in hematooncology by Mihalyova, Jana, Jelinek, Tomas, Growkova, Katerina, Hrdinka, Matous, Simicek, Michal, Hajek, Roman

“…•Cancer cells survive via overexpressed anti-apoptotic BCL2 proteins.•Venetoclax is highly selective BCL2 inhibitor with an acceptable toxicity…”
Get full text

Selinexor, selective inhibitor of nuclear export: Unselective bullet for blood cancers by Benkova, Katerina, Mihalyova, Jana, Hajek, Roman, Jelinek, Tomas

“…Exportin 1 (XPO1), also known as chromosome maintenance 1 protein (CRM1), is the main transporter for hundreds of proteins like tumor suppressors, growth…”
Get full text

P-092 Monitoring of Anti-BCMA CAR-T Cells and non-CAR-T Immune Subsets in Multiple Myeloma Patients by Venglar, Ondrej, Viera, Hrabcakova, Soucek, Ondrej, Kutejova, Kamila, Mihalyova, Jana, Muronova, Ludmila, Popkova, Tereza, Zihala, David, Sevcikova, Tereza, Broskevicova, Lucie, Hájek, Roman, Folber, Frantisek, Radocha, Jakub, Jelinek, Tomas

Get full text

Single‐agent venetoclax induces MRD‐negative response in relapsed primary plasma cell leukemia with t(11;14) by Jelinek, Tomas, Mihalyova, Jana, Kascak, Michal, Duras, Juraj, Popkova, Tereza, Benkova, Katerina, Richterova, Petra, Plonkova, Hana, Zuchnicka, Jana, Broskevicova, Lucie, Huvarova, Lucie, Cerna, Lucie, Growkova, Katerina, Simicek, Michal, Havel, Martin, Gumulec, Jaromir, Navratil, Milan, Koristek, Zdenek, Paiva, Bruno, Hajek, Roman

Get full text

Second Line Treatment with Bruton Tyrosine Kinase Inhibitor (BTKi) or Bcl-2 Inhibitor (Bcl-2i) in Patients with Chronic Lymphocytic Leukemia (CLL): Primary Analysis of the Czech Study Group for CLL (CSCLL) by Mihalyova, Jana, Panovska, Anna, Simkovic, Martin, Turcsanyi, Peter, Spacek, Martin, Brejcha, Martin, Lysak, Daniel, Mocikova, Heidi, Pavlova, Sarka, Chrapava, Marika, Zuchnicka, Jana, Brychtova, Yvona, Vodarek, Pavel, Urbanova, Renata, Likarova, Tereza, Malcikova, Jitka, Jurkova, Tereza, Lancova, Klara, Bezdekova, Lucie, Papajik, Tomas, Baranova, Jana, Arpas, Tomas, Pospisilova, Sarka, Smolej, Lukas, Doubek, Michael

“…Introduction: Venetoclax in combination with rituximab (VenR) along with either ibrutinib or acalabrutinib monotherapy represent the most common regimens…”
Get full text

Cytarabine + G-CSF is more effective than cyclophosphamide + G-CSF as a stem cell mobilization regimen in multiple myeloma by Jelinek, Tomas, Adamusova, Lucie, Popkova, Tereza, Tvrda, Ivana, Smejkalova, Jana, Simicek, Michal, Salounova, Dana, Kascak, Michal, Mihalyova, Jana, Plonkova, Hana, Duras, Juraj, Navratil, Milan, Hajek, Roman, Koristek, Zdenek

“…Cyclophosphamide (Cy) plus granulocyte-colony stimulating factor (G-CSF) is currently a standard regimen for hematopoietic stem cell (HSC) mobilization in…”
Get full text

Towards Higher Safety of Haemato-Oncological Patients Undergoing Treatment by Popkova, Tereza, Hradska, Katarina, Mihalyova, Jana, Skorupova, Michaela, Jelinek, Tomas, Duras, Juraj, Koristek, Zdenek, Navratil, Milan, Benkova, Katerina, Plonkova, Hana, Zuchnicka, Jana, Gumulec, Jaromir, Hajek, Roman

“…Introduction: Medical care has recently been moving from wards to outpatient clinics due to a growing number of patients, convenient therapeutic approaches and…”
Get full text

Characterization of Infectious Complications during the Expected Duration of Cytokine Release Syndrome (CRS) in Patients Receiving CAR T Cell Therapy – Are We over-Treating with Anti-Microbials? by Mihalyova, Jana, Ahmad, Sana, Handa, Shivani, Azzi, Jacques, Rossi, Adriana, Richard, Shambavi, Jagannath, Sundar, Osman, Keren, Keyzner, Alla, Ibrahim, Uroosa

“…Management of cytokine release syndrome (CRS) following CAR T cell therapy includes extensive workup to exclude infectious causes of fever. Patients are…”
Get full text

Venetoclax plus bortezomib and dexamethasone in heavily pretreated end‐stage myeloma patients without t(11;14): A real‐world cohort by Jelinek, Tomas, Popkova, Tereza, Duras, Juraj, Mihalyova, Jana, Kascak, Michal, Benkova, Katerina, Plonkova, Hana, Cerna, Lucie, Koristek, Zdenek, Simicek, Michal, Hajek, Roman

Get full text